Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals Inc. celebrates the Japanese approval of LUPKYNIS (voclosporin) to treat lupus nephritis, marking a significant milestone in collaboration with Otsuka Pharmaceutical. This approval, backed by the AURORA Clinical Program’s positive data, will address the high incidence of the disease in Japan. Additionally, Aurinia is set to receive a $10 million payment and royalties on net sales in Japan.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
